Literature DB >> 28514718

Exploring the neuroprotective effects of ginkgolides injection in a rodent model of cerebral ischemia-reperfusion injury by GC-MS based metabolomic profiling.

Jian-Liang Geng1, Ji-Ye Aa1, Si-Qi Feng1, Shu-Yao Wang2, Pei Wang1, Yue Zhang1, Bing-Chen Ouyang1, Jian-Kun Wang1, Ye-Jin Zhu1, Wen-Zhe Huang2, Zhen-Zhong Wang2, Wei Xiao3, Guang-Ji Wang4.   

Abstract

Cerebral ischemia-reperfusion (I/R) injury usually contributes to mortality and disability after ischemic stroke. Ginkgolides injection (GIn), a standard preparation composed of ginkgo diterpene lactones extract, is clinically used for neuroprotective treatment on reconvalescents of cerebral infarction. However, the understanding about its therapeutic mechanism is still lacking. In this study, a gas chromatography-mass spectrometry (GC-MS) based metabolomic approach coupled with multivariate data analysis (MVDA) was applied to explore the neuroprotective effects of GIn in a rodent model of focal ischemic stroke induced by transient middle cerebral artery occlusion (tMCAO). Metabolomic profiling revealed a series of metabolic perturbations that underlie the cerebral I/R pathological events. GIn can reverse the I/R induced brain metabolic deviations by modulating multiple metabolic pathways, such as glycolysis, Krebs cycle, pentose phosphate pathway (PPP), γ-aminobutyrate (GABA) shunt and lipid metabolism. Moreover, the main bioactive components of GIn were distributed to brain tissue much more easily in tMCAO rats than in normal rats after an intravenous administration, suggesting that the increased cerebral exposure to ginkgolides in I/R pathological condition potentially facilitated the neuroprotective effects of GIn by directly targeting at brain. The present study provided valuable information for our understanding about metabolic changes of cerebral I/R injury and clinical application of GIn.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebral exposure level; Cerebral ischemia–reperfusion injury; Ginkgolides injection; Metabolomic profiling; Neuroprotection

Mesh:

Substances:

Year:  2017        PMID: 28514718     DOI: 10.1016/j.jpba.2017.04.031

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Effects of ginkgo diterpene lactone on brain inflammation and oxidative stress in rats with cognitive impairment of cerebral small vessel disease.

Authors:  Shan Jiang; Xianjun Ma; Yinyi Chen; Baodong Gu; Na Sun; Hui Xiao
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 2.  Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications.

Authors:  Hui Xu; Emily Wang; Feng Chen; Jianbo Xiao; Mingfu Wang
Journal:  Oxid Med Cell Longev       Date:  2021-04-28       Impact factor: 6.543

3.  Investigating the Protective Effect of Gross Saponins of Tribulus terrestris Fruit against Ischemic Stroke in Rat Using Metabolomics and Network Pharmacology.

Authors:  Yang Wang; Wenjun Guo; Yue Liu; Jifeng Wang; Meiling Fan; Hongyu Zhao; Shengxu Xie; Yajuan Xu
Journal:  Metabolites       Date:  2019-10-21

4.  Deciphering the Underlying Mechanisms of Formula Le-Cao-Shi Against Liver Injuries by Integrating Network Pharmacology, Metabonomics, and Experimental Validation.

Authors:  Qing Zhao; Xia Ren; Shu-Yue Song; Ri-Lei Yu; Xin Li; Peng Zhang; Chang-Lun Shao; Chang-Yun Wang
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

Review 5.  Metabolic Reprogramming: Strategy for Ischemic Stroke Treatment by Ischemic Preconditioning.

Authors:  Jing Liang; Rongrong Han; Bing Zhou
Journal:  Biology (Basel)       Date:  2021-05-11

6.  Ginkgo biloba extract and its diterpene ginkgolide constituents ameliorate the metabolic disturbances caused by recombinant tissue plasminogen activator in rat prefrontal cortex.

Authors:  Zhi Chen; Shunjie Bai; Qingchuan Hu; Peng Shen; Ting Wang; Zihong Liang; Wei Wang; Xunzhong Qi; Peng Xie
Journal:  Neuropsychiatr Dis Treat       Date:  2018-07-04       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.